Can't see a deal of this magnitude being factored in already. It makes ACR a serious player with much more stability and longevity. US$335 is about AU$360m and that is without any royalty payments to speak of. Like I said that works out to $2/share over the long term. $200m of it is contingent on success but the indications are great.
It gives us a workable and realistic trajectory, as opposed to a potential one.
Having said all that I have no idea what will happen to the SP but I'm hoping for $3.50.
lilly to acquire global license to axiron, page-8
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
